Polymorphisms of the receptor for advanced glycation end-products and glyoxalase I in patients with renal cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10294315" target="_blank" >RIV/00216208:11110/15:10294315 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/15:10294315 RIV/00064203:_____/15:10294315 RIV/00064165:_____/15:10294315

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s13277-014-2821-0" target="_blank" >http://dx.doi.org/10.1007/s13277-014-2821-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s13277-014-2821-0" target="_blank" >10.1007/s13277-014-2821-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Polymorphisms of the receptor for advanced glycation end-products and glyoxalase I in patients with renal cancer

Popis výsledku v původním jazyce

The receptor for advanced glycation end products (RAGE) and its ligands are involved in the pathogenesis of cancer. Glyoxalase I (GLO1) is an enzyme which detoxifies advanced glycation end product (AGE) precursors. The aim of the study was to find out the relationship between four polymorphisms (single nucleotide polymorphism, SNP) of the RAGE gene (AGER) and one SNP of the GLO1 gene and clear cell renal cancer (ccRCC). All polymorphisms (rs1800625 RAGE -429T/C, rs1800624 -374T/A, rs3134940 2184A/G, rs2070600 557G/A (G82S), and GLO1 rs4746 419A/C(E111A)) were determined by PCR-RFLP in 214 patients with ccRCC. A group of 154 healthy subjects was used as control. We found significant differences in the allelic and genotype frequencies of GLO1 E111A (419A/C) SNP between patients and controls-higher frequency of the C allele in ccRCC-58.6 vs. 44.5 % in controls, OR (95 % CI) 1.77 (1.32-2.38), p = 0.0002 (corrected p = 0.001); OR (95 % CI) CC vs. AA 2.76 (1.5-4.80), p = 0.0004 (corrected p

Název v anglickém jazyce

Polymorphisms of the receptor for advanced glycation end-products and glyoxalase I in patients with renal cancer

Popis výsledku anglicky

The receptor for advanced glycation end products (RAGE) and its ligands are involved in the pathogenesis of cancer. Glyoxalase I (GLO1) is an enzyme which detoxifies advanced glycation end product (AGE) precursors. The aim of the study was to find out the relationship between four polymorphisms (single nucleotide polymorphism, SNP) of the RAGE gene (AGER) and one SNP of the GLO1 gene and clear cell renal cancer (ccRCC). All polymorphisms (rs1800625 RAGE -429T/C, rs1800624 -374T/A, rs3134940 2184A/G, rs2070600 557G/A (G82S), and GLO1 rs4746 419A/C(E111A)) were determined by PCR-RFLP in 214 patients with ccRCC. A group of 154 healthy subjects was used as control. We found significant differences in the allelic and genotype frequencies of GLO1 E111A (419A/C) SNP between patients and controls-higher frequency of the C allele in ccRCC-58.6 vs. 44.5 % in controls, OR (95 % CI) 1.77 (1.32-2.38), p = 0.0002 (corrected p = 0.001); OR (95 % CI) CC vs. AA 2.76 (1.5-4.80), p = 0.0004 (corrected p

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CE - Biochemie

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Tumor Biology

ISSN

1010-4283

e-ISSN

—

Svazek periodika

36

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

6

Strana od-do

2121-2126

Kód UT WoS článku

000351884000088

EID výsledku v databázi Scopus

2-s2.0-84930912526